Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06720714 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women
A Phase 1 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT06720714 is a Phase 1 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 15 participants.
The verdict
NCT06720714, a Phase 1 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the concentration of rozanolixizumab in mature breast milk of healthy study participants following administration of a single dose of rozanolixizumab
Interventions
- DRUG Rozanolixizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2025-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06720714
The ClinicalTrials.gov registry entry for NCT06720714 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rozanolixizumab is the first listed.
NCT06720714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06720714 about?
NCT06720714 is a clinical study titled "A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women". The purpose of the study is to assess the concentration of rozanolixizumab in mature breast milk of healthy study participants following administration of a single dose of rozanolixizumab
What is the current status of trial NCT06720714?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-12-03. Estimated completion is 2025-05-12.
What interventions are being tested in trial NCT06720714?
The interventions under investigation include: Rozanolixizumab (DRUG).
Who is sponsoring clinical trial NCT06720714?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.